Inoue Kenji, Masumoto Mieko, Wakakura Masato, Tomita Goji
Inouye Eye Hospital, Tokyo, Japan;
Clin Ophthalmol. 2011;5:393-6. doi: 10.2147/OPTH.S17527. Epub 2011 Mar 22.
To prospectively evaluate the safety, hypotensive effect, and preservation of visual fields of dorzolamide when added to latanoprost.
This study included 46 patients (46 eyes) with primary open-angle glaucoma who had been treated with latanoprost. Dorzolamide (1%) was added to latanoprost, and the intraocular pressure (IOP) was monitored before and after 3, 6, and 12 months. The mean deviation shown by Humphrey perimetry was compared before and after twelve months of treatment. Adverse reactions were monitored over the 12-month study period.
The mean baseline IOP was 17.2 ± 3.0 mmHg while those after 3, 6 and 12 months of treatment were 14.9 ± 3.0 mmHg, 14.5 ± 3.2 mmHg, and 14.6 ± 2.6 mmHg respectively (P < 0.0001, 1-β(power) = 0.9999571). The absolute reduction of IOP and the percent reduction were similar after 3, 6, and 12 months of treatment. The mean deviation on Humphrey perimetry was similar before and after twelve months of treatment. Three patients discontinued dorzolamide therapy due to elevation of IOP and one patient discontinued it because of adverse reactions.
Dorzolamide is safe and effective when used for twelve months as add-on therapy to latanoprost for open-angle glaucoma.
前瞻性评估多佐胺添加到拉坦前列素中时的安全性、降压效果及视野保留情况。
本研究纳入46例（46只眼）接受过拉坦前列素治疗的原发性开角型青光眼患者。在拉坦前列素基础上加用多佐胺（1%），并在3、6和12个月前后监测眼压。比较治疗12个月前后 Humphrey 视野计显示的平均偏差。在12个月的研究期间监测不良反应。
平均基线眼压为17.2±3.0 mmHg，而治疗3、6和12个月后的眼压分别为14.9±3.0 mmHg、14.5±3.2 mmHg和14.6±2.6 mmHg（P<0.0001，检验效能1-β=0.9999571）。治疗3、6和12个月后眼压的绝对降低值和降低百分比相似。治疗12个月前后 Humphrey 视野计的平均偏差相似。3例患者因眼压升高停用多佐胺治疗，1例患者因不良反应停药。
多佐胺作为原发性开角型青光眼拉坦前列素的附加治疗使用12个月时安全有效。
